Ozempic Lawsuit | Ozempic and Wegovy Claims

The multidistrict litigation (MDL) for GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, reached a significant milestone with the filing of a Master Complaint.

This consolidated filing presents common allegations against drug manufacturers Novo Nordisk and Eli Lilly, accusing them of failing to sufficiently warn about severe gastrointestinal side effects such as gastroparesis, intestinal obstruction, and ischemic bowel.

The litigation currently involves over 1,200 claims and is expected to grow as more individuals connect their injuries to these medications.

The Master Complaint includes a variety of claims, such as:

• Failure to Warn
• Fraudulent Concealment
• Negligent Design
• Strict Liability for Design Defects
• Wrongful Death and Loss of Consortium

Judge Karen S. Marston, who is overseeing the MDL in the Eastern District of Pennsylvania, is anticipated to approve a Short Form Complaint soon.

This will simplify the process for future plaintiffs, allowing them to adopt the Master Complaint’s allegations and add their specific details.

Moving forward, key issues will be addressed, including setting standards for diagnostic evidence and preparing for bellwether trials.

These trials, while not directly impacting other cases, may influence settlement negotiations in the expanding litigation.

If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.

Contact TruLaw for a free consultation.

You can also use the chatbot on this page for an instant case evaluation.

The Ozempic Lawsuit is ongoing. 

The Ozempic Lawsuit continues to grow, with claims asserting that the diabetes medication Ozempic has led to severe gastrointestinal side effects, including gastroparesis (stomach paralysis), nausea, and vomiting.

Plaintiffs allege that Novo Nordisk, the drug’s manufacturer, failed to adequately warn patients and healthcare providers of these risks.

In October, there were 1,090 cases filed in the Ozempic lawsuit, rising to 1,221 in November, with an additional 131 filings.

Gastroparesis, one of the primary side effects cited, can lead to chronic nausea, vomiting, and malnutrition, significantly affecting quality of life.

If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.

Contact TruLaw for a free consultation.

You can also use the chatbot on this page for an instant case evaluation.

October 14, 2024

The Ozempic Lawsuit is ongoing. 

The FDA is currently reevaluating its recent decision to remove Eli Lilly’s obesity and diabetes medications, Zepbound and Mounjaro, from the shortage list, allowing compounding pharmacies to continue producing their versions temporarily.

This reevaluation comes after the Outsourcing Facilities Association (OFA) filed a lawsuit, arguing that the FDA’s decision ignored evidence of ongoing supply shortages.

The lawsuit, filed in the U.S. District Court for the Northern District of Texas, claims that the FDA failed to follow federal procedures by not providing notice or allowing public comment before removing these drugs from the shortage list.

In response, the FDA has agreed to revisit its decision and permit compounders to continue manufacturing the drugs while discussions continue.

A status report from both parties is expected by November 21.

This legal battle underscores ongoing supply chain issues with popular GLP-1 medications like Zepbound, Mounjaro, and Novo Nordisk’s Wegovy, all of which have seen surging demand.

Despite efforts by Lilly and Novo to ramp up production, shortages remain, particularly for the initial “starter” doses of Wegovy, which is still listed as being in shortage by the FDA.

If you or a loved one experienced severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may qualify to file an Ozempic Lawsuit. 

Contact the Ozempic Lawyers at TruLaw for a free consultation, or use the chatbot on this page to determine if you qualify for a case instantly.

October 1, 2024

The Ozempic Lawsuit is ongoing.

The Ozempic Lawsuit focuses on claims that the diabetes and weight loss medication, Ozempic, has caused severe gastrointestinal issues, including gastroparesis (paralysis of the stomach), nausea, vomiting, and other serious side effects.

Plaintiffs allege that manufacturers Novo Nordisk and Eli Lilly failed to adequately warn patients and healthcare providers about the risks associated with Ozempic and other GLP-1 drugs.

In September, 869 cases were filed in the Ozempic MDL.

By October, the number of pending Ozempic Lawsuits had risen significantly to 1,090, an increase of 221 filings.

Ozempic, along with other GLP-1 weight loss medications, is primarily used to manage blood sugar levels in individuals with type 2 diabetes.

However, these drugs have been linked to severe digestive issues such as gastroparesis, a condition that delays stomach emptying, resulting in persistent nausea, vomiting, and even malnutrition.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other serious health issues after taking Ozempic or similar medications, you may be eligible to file a lawsuit against the drug manufacturers.

Contact the Ozempic Attorneys at TruLaw for a free consultation. 

You can also use the chatbot on this page for a free case review to see if you qualify to file an Ozempic Lawsuit instantly.

September 11, 2024

The Ozempic Lawsuit is ongoing. 

The multidistrict litigation (MDL) against pharmaceutical giants Novo Nordisk and Eli Lilly, involving GLP-1 drugs such as Ozempic, Wegovy, Trulicity, and Mounjaro, continues to progress as plaintiffs claim these medications have caused serious gastrointestinal injuries.

The primary allegation is that these drugs are linked to gastroparesis, a condition that paralyzes stomach muscles.

With over 900 complaints consolidated into this MDL, 85% of the cases cite gastroparesis as a primary injury.

Recently, both sides presented key scientific evidence during a “science day” session, a common event in large-scale pharmaceutical lawsuits.

This session allowed attorneys and experts to discuss critical data regarding the drugs, their effects, and the underlying medical science.

Central to the plaintiffs’ argument is the claim that these medications cause gastroparesis, while the defense contends that the drugs are designed to delay gastric emptying, which they argue is distinct from gastroparesis.

This technical difference is a key point in the defense’s argument.

Despite these defenses, plaintiffs’ attorneys emphasize the real-life impact of gastroparesis on their clients, which they believe will be more compelling in court.

No trial date has been set yet, but the “science day” laid essential groundwork for the future of this litigation.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic or other GLP-1 drugs, you may be eligible to file an Ozempic Lawsuit against the drug manufacturers.

Contact the Ozempic Attorneys at TruLaw for a free consultation. 

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

September 9, 2024

The Ozempic Lawsuit is ongoing.

A recent report highlights that Ozempic and other weight loss drugs, including Wegovy, have been linked to 162 deaths in the U.S. over the past six years, according to data from the FDA Adverse Event Reporting System (FAERS).

Although these deaths haven’t been definitively proven to be caused by semaglutide, the active ingredient in these drugs, they were mentioned as factors in the fatalities.

The FAERS database has recorded 62,000 adverse reactions to these drugs, with 10,000 classified as serious.

Despite the growing concerns and reports of side effects, including gastrointestinal issues, pancreas inflammation, and gallbladder problems, the drugs continue to be widely used for weight loss.

Furthermore, in the MDL involving Ozempic and other GLP-1 medications, the U.S. District Court is evaluating whether plaintiffs must provide specific diagnostic testing to prove that they developed gastroparesis.

Specific diagnostic testing refers to a medical process where precise tests, such as gastric emptying studies, are used to confirm whether a patient has a particular condition, such as gastroparesis, by objectively measuring how well the stomach empties food into the intestines.

Additionally, the court will consider if the claims are preempted by federal law and determine whether GLP-1 drugs like Ozempic can cause the injuries in question, with decisions expected to impact the progression and potential settlement of these lawsuits.

“Preempted by federal law” means that federal regulations take precedence over state laws, preventing states from enforcing their own laws if they conflict with federal rules.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

September 4, 2024

The Ozempic weight loss litigation is advancing, with Science Day scheduled to take place soon.

Science Day is a key hearing in mass tort cases where both sides present evidence, typically including scientific studies, key documents, and expert testimonies. 

The hearing’s purpose is to provide the Court with a comprehensive understanding of the product and the main issues at hand.

Each judge approaches Science Day differently, but it’s usually one of the first opportunities for the Court to dive into the details of the case.

The hearing typically lasts several hours, featuring presentations and open dialogue in a question-and-answer format.

For the Ozempic litigation, Science Day will give all parties a clearer view of the upcoming legal proceedings.

After Science Day, Judge Marston has scheduled monthly Case Management Conferences in September, October, November, and December, indicating that this litigation is expected to pick up speed as the year progresses

If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.

Contact TruLaw for a free consultation.

You can also use the chatbot on this page for an instant case evaluation.

September 1, 2024

The number of Ozempic lawsuits has grown significantly, increasing from 346 in August to 869 in September.

Ozempic, which contains semaglutide as its active ingredient, has been associated with serious gastrointestinal problems, including gastroparesis (delayed stomach emptying) and pancreatitis.

Additionally, some users have reported thyroid tumors and other severe health complications.

These risks have prompted numerous lawsuits against Novo Nordisk, with allegations that the company failed to provide sufficient warnings about these potential dangers.

If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.

Contact TruLaw for a free consultation.

You can also use the chatbot on this page for an instant case evaluation.

August 8, 2024

The Ozempic Lawsuit is ongoing, and our lawyers are accepting new clients.

Gastroparesis is a condition in which the stomach empties its contents into the small intestine more slowly than normal.

Common symptoms include nausea, vomiting, bloating, feeling full quickly, and abdominal pain.

Potential causes include diabetes, surgeries, infections, and certain medications.

Common Causes of Gastroparesis:

• Idiopathic: Accounts for about 50% of cases with no identifiable cause.
• Diabetes: More common in type 1 diabetes but also occurs in type 2.
• Post-surgical: Often occurs after surgeries impacting the stomach or vagal nerve.
• Postinfectious: Usually self-limiting but can sometimes lead to chronic issues.

How Does Ozempic Work?

Ozempic (semaglutide) is a medication primarily used for managing type 2 diabetes.

It functions by mimicking a hormone called GLP-1, which regulates blood sugar levels.

Ozempic boosts insulin production and slows the rate at which food leaves the stomach, aiding in blood sugar stabilization.

This slowing effect can also promote weight loss by prolonging the sensation of fullness.

Link Between Ozempic and Gastroparesis

Ozempic slows stomach emptying to help manage blood sugar, but this can worsen or trigger gastroparesis in some individuals.

This side effect has resulted in lawsuits against Novo Nordisk for allegedly not providing adequate warnings to users.

As a GLP-1 agonist, Ozempic mimics a hormone that delays food movement through the digestive tract, leading to symptoms like nausea and vomiting.

For those already prone to delayed gastric emptying, Ozempic can exacerbate the condition.

Numerous lawsuits argue that Novo Nordisk should have better communicated the risks of severe gastrointestinal side effects, including gastroparesis.

If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.

Contact TruLaw for a free consultation.

You can also use the chatbot on this page for an instant case evaluation.

August 1st, 2024

The Ozempic Lawsuit is ongoing, and our lawyers are accepting new clients.

The lawsuit centers on claims against Novo Nordisk, the manufacturer of Ozempic, a popular medication used for the treatment of type 2 diabetes.

Plaintiffs allege that Ozempic causes severe gastrointestinal issues, including gastroparesis, which can lead to debilitating symptoms such as nausea, vomiting, and severe abdominal pain.

These side effects have prompted numerous individuals to file lawsuits, arguing that Novo Nordisk failed to adequately warn users of these potential risks.

According to recent filings, the number of cases related to the Ozempic Lawsuit has been steadily increasing.

As of August 1st, there are 346 cases pending, the same amount as July.

The lawsuits argue that Novo Nordisk was aware, or should have been aware, of the potential for these severe side effects but failed to provide sufficient warnings to consumers and healthcare professionals.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TruLaw for a free consultation. 

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

A recent study published in JAMA Ophthalmology indicates that patients using Ozempic and Wegovy may have a higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition leading to sudden vision loss.

Key findings include:

• Diabetic patients on Semaglutide medications are over four times more likely to develop NAION.
• Overweight or obese individuals using these drugs face a sevenfold increase in risk.
• Approximately 100 cases were identified annually over six years, with the highest risk observed within the first year of medication use.

Novo Nordisk, the manufacturer of Ozempic and Wegovy, acknowledges the study but maintains that the data does not establish causation.

Despite the potential risk, NAION remains relatively uncommon compared to the benefits provided by these medications.

The U.S. Food and Drug Administration (FDA) lists vision changes among the possible side effects of semaglutide.

Novo Nordisk is conducting ongoing trials to explore the link between semaglutide use and diabetic retinopathy, with results expected by 2027.

Experts recommend that patients taking semaglutide or considering treatment discuss the risks and benefits with their doctors, particularly those with other optic nerve issues such as glaucoma or preexisting visual loss.

If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.

Contact TruLaw for a free consultation.

You can also use the chatbot on this page for an instant case evaluation.

June 26, 2024

A recent study from the University of Copenhagen raises new concerns about GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, highlighting potential bone density loss.

Published in JAMA Network Open, the study found that using these medications without combining them with exercise can lead to a decrease in bone mineral density (BMD) in critical areas like the hips and spine.

Ozempic, initially approved for Type 2 diabetes in 2017, has gained popularity as a weight loss drug. Its active ingredient, semaglutide, is also present in Wegovy, a higher-dose version specifically for weight loss.

Despite aggressive marketing promoting these drugs as safe and effective, GLP-1 medications have been linked to severe health risks, including gastroparesis—a condition where the stomach is paralyzed, leading to long-term gastrointestinal issues.

Thousands of lawsuits have been filed against the manufacturers for allegedly failing to warn about these risks, prioritizing profits over consumer safety.

The latest study by Dr. Simon Birk Jensen and colleagues involved a randomized clinical trial with 195 participants.

The findings revealed that participants who combined GLP-1 treatment with exercise achieved the most significant weight loss while maintaining bone health.

Those who used Victoza alone experienced a decrease in BMD.

The study showed the necessity of exercise to mitigate the decrease in bone mineral density associated with GLP-1 medications.

If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.

Contact TruLaw for a free consultation.

You can also use the chatbot on this page for an instant case evaluation.

June 25, 2024

Recent research highlights a significant concern for users of glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly prescribed for diabetes management.

A study published in Gastroenterology on March 27, 2024, indicates an increased risk of aspiration pneumonia associated with GLP-1RA use during endoscopic procedures involving propofol sedation targeting the upper gastrointestinal tract.

The retrospective cohort study analyzed health records from 80 healthcare organizations, involving adults aged 21 to 70 who underwent upper and lower endoscopies between 2018 and 2020.

Results show that GLP-1RA users, defined as individuals with a history of use exceeding six months and with at least two refills within six months prior to the procedure, experienced a higher incidence rate of aspiration pneumonia (0.83%) compared to nonusers (0.63%), corresponding to a hazard ratio of 1.33.

This risk was notably higher in procedures involving propofol sedation, specifically upper GI endoscopies, with no significant risk noted in lower GI procedures.

Dr. Ali Rezaie, Medical Director of Gastroenterology Motility at Cedars-Sinai Medical Center, emphasized the need for context, noting that while the relative risk increases by 33%, the absolute risk remains low at 0.2%.

Conversely, the American Gastroenterological Association has not found evidence to support this precaution in their latest clinical update.

Despite this, some medical centers, including Cedars-Sinai, have begun advising patients to discontinue GLP-1RA use one week prior to elective procedures.

Further guidance is expected as new recommendations are being developed, reflecting a cautious approach towards managing the increased risk of aspiration in GLP-1RA users.

If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.

You can also use the chatbot on this page for an instant case evaluation.

June 21, 2024

A mass tort lawsuit is currently underway in a federal court in Philadelphia, addressing serious concerns regarding the safety and regulatory oversight of widely used weight-loss medications including Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro.

These drugs, primarily known as GLP-1 agonists, were initially approved for managing Type 2 diabetes but have gained popularity for weight loss purposes.

Recent data reveals a significant surge in their usage, with over 15 million Americans using these medications as of last month, marking a substantial increase in prescriptions by 40 times since 2018.

The core of the lawsuit alleges that Novo Nordisk and Eli Lilly, the manufacturers of these drugs, failed to provide sufficient warnings about potential severe gastrointestinal side effects.

Reported adverse effects include gastroparesis, intestinal obstructions, and pancreatitis, concerns that have been substantiated by recent studies and warnings from the Food and Drug Administration (FDA).

Legal experts indicate that this case not only scrutinizes the drug manufacturers but also casts doubt on the FDA’s approval and monitoring processes.

The ramifications of this lawsuit could extend beyond the courtroom, potentially leading to stricter regulatory measures for GLP-1 agonists and impacting their future market availability and consumer trust.

Amidst growing endorsements from celebrities and increasing awareness of their health benefits, these weight-loss drugs have experienced a surge in demand.

However, the ongoing lawsuit and the negative publicity surrounding it could temper future demand.

he outcome of this litigation holds significant implications for drug safety perceptions and the broader regulatory landscape of pharmaceuticals.

If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.

You can also use the chatbot on this page for an instant case evaluation.

June 7, 2024

The Ozempic lawsuit is growing as more consumers become aware of GLP-1 side effects.

The U.S. Judicial Panel on Multidistrict Litigation (JPML) has recently transferred the combined litigation concerning Ozempic, Wegovy, and Mounjaro to U.S. District Judge Karen Marston in the Eastern District of Pennsylvania, following the unexpected passing of U.S. District Judge Gene E.K. Pratter.

Under the oversight of Judge Marston, the case now encompasses over 10,000 personal injury claims.

This litigation centers on serious claims against pharmaceutical giants Novo Nordisk and Eli Lilly and Co., alleging that they failed to adequately warn users about potential severe digestive side effects associated with these GLP-1 class drugs, which are commonly prescribed for diabetes management and weight loss.

Plaintiffs have linked these medications to severe health issues such as gastroparesis, intense vomiting, and bowel obstruction.

Significant legal proceedings include the completion of the plaintiff’s fact sheet, which will outline each claimant’s injuries, medical conditions, and specific drug usage.

While defense attorneys see this phase as a chance to potentially reduce the case’s breadth by dismissing claims related to counterfeit products or those without proper medical diagnoses, plaintiffs’ lawyers are contesting any premature dismissals.

They advocate for further discovery and the initiation of bellwether trials to comprehensively address and resolve the allegations.

Given the substantial public attention and the extensive use of these medications—reported to be used by one in eight U.S. adults—Judge Marston is expected to move forward with these proceedings.

If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.

You can also use the chatbot on this page for an instant case evaluation.

May 29, 2024:

The Ozempic lawsuit is growing as more consumers become aware of GLP-1 side effects.

The Ozempic lawsuit continues to gain attention as increasing numbers of consumers report severe side effects from GLP-1 receptor agonists, including Ozempic and Wegovy, which doctors frequently prescribe for managing obesity and diabetes.

Concerns are escalating about the risk of gastroparesis, a condition commonly known as stomach paralysis, which is often associated with these medications.

Gastroparesis slows down gastric emptying, leading to significant discomfort and complicating the management of metabolic diseases.

Recent studies highlight the risk of developing gastroparesis from GLP-1 medication use:

• Research unveiled at Digestive Week 2024 indicates a rise in gastroparesis occurrences in patients using GLP-1 drugs compared to those not taking these medications.

• A University of Kansas study, which reviewed health records of nearly 150,000 patients, found a 66% increased diagnosis rate of gastroparesis among individuals treated with GLP-1s.

• Further research by University Hospitals in Cleveland, examining over 336,000 individuals, discovered that the likelihood of developing gastroparesis increases after six months of GLP-1 therapy.

Although the overall risk is less than 1%, the data consistently show a significant relative increase.

As the popularity of Ozempic and Wegovy persists in diabetes and obesity management, ongoing investigations into their side effects, such as gastroparesis, are essential for patient safety.

Our Ozempic lawyers are actively investigating cases involving stomach paralysis and other severe side effects from these medications.

If you or a loved one used Ozempic, Wegovy, or compounded versions of the drugs, and subsequently developed gallbladder disease, stomach paralysis (gastroparesis), cyclic vomiting syndrome, or other related health problems, you may be eligible to file an Ozempic Lawsuit claim.

Contact TruLaw for a free consultation.

You can also use the chatbot on this page for an instant case evaluation.

May 23, 2024

Awareness surrounding Ozempic and other GLP-1 drugs continues to grow.

The Ozempic multidistrict litigation is facing an unexpected complication due to the abrupt and tragic passing of U.S. District Judge Gene E.K. Pratter on May 17, 2024.

Judge Pratter, who was presiding over the Ozempic MDL in the Eastern District of Pennsylvania, passed away at the age of 75.

Judge Pratter’s death may have an impact on the ongoing Ozempic Lawsuits, which allege severe gastrointestinal side effects from glucagon-like peptide-1 (GLP-1) receptor agonists used in diabetes and weight loss treatments.

Some estimates indicate that nearly 2% of the U.S. population has been prescribed one of the GLP-1 medications, either for diabetes treatment or weight loss, it was widely expected that the litigation would become a major mass tort in the coming months.

These lawsuits claim that the drug manufacturers, including Novo Nordisk and Eli Lilly, failed to adequately warn users about the risks of medications such as Ozempic, Wegovy, and Mounjaro.

At the time of her passing, Judge Pratter was managing the initial stages of the MDL, which had been formed in February 2024, the MDL included 87 active lawsuits as of May 1, with expectations that the number could grow to several thousand due to the widespread use of these medications.

The reassignment of these cases to a new judge is now necessary, a process that will involve the review of existing records and a thorough understanding of the scientific and medical evidence, which could delay the proceedings.

A planned “Ozempic Science Day” on June 14, intended to clarify the scientific claims of the litigation, is now uncertain.

As the judicial system manages this transition, the continuity of the Ozempic MDL will be a priority.

If you or a loved one has suffered injuries from Ozempic or other GLP-1 drugs, you may be eligible to file a claim. 

Contact us for a free consultation, or use the chatbot on this page to find out if you qualify for the Weight Loss Drugs Lawsuit.

May 21, 2024

Awareness surrounding Ozempic and other GLP-1 drugs continues to grow.

Growing concerns have surfaced regarding the serious side effects of Ozempic, a popular weight loss medication.

Medical professionals and patients report a range of adverse reactions linked to this drug and other GLP-1 medications.

A detailed examination reveals more than 9 million prescriptions of Ozempic were issued in the fourth quarter of 2022 alone.

Despite the high prescription rates, the number of users could be substantially higher, as many individuals obtain the drug without proper medical oversight due to insurance constraints.

Our Ozempic lawyers are closely monitoring the situation, as patients report severe side effects such as gastroparesis (stomach paralysis), gallbladder disease, cyclic vomiting syndrome, and more.

If you or a loved one has suffered injuries from Ozempic or other GLP-1 drugs, you may be eligible to file a claim. 

Contact us for a free consultation, or use the chatbot on this page to find out if you qualify for the Weight Loss Drugs Lawsuit.

May 9, 2024

The Ozempic Lawsuit is progressing through the early stages in multidistrict litigation. 

On May 9, 2024, U.S. District Judge Gene Pratter of Philadelphia officially appointed four attorneys as lead counsel in the multidistrict litigation (MDL) against diet drug manufacturers Novo Nordisk and Eli Lilly.

The legal proceedings have garnered attention not only for the nature of the claims but also for the nature of the claims but also for the innovative approach to selecting lead counsel, which could set a precedent for future large-scale litigations.

Judge Pratter’s method involves a combination of self-selection by a state of proposal lead counsels and confirmation through consensus among other plaintiffs’ lawyers.

The process led by Judge Pratter aims to streamline the complex management of thousands of cases in the Ozempic MDL.

As the Ozempic cases progress, the spotlight remains on the safety profile of these drugs.

Plaintiffs allege that side effects were not fully disclosed, impacting patient health when used as prescribed for diabetes management and weight loss.

Novo Nordisk has defended the safety of Ozempic by stating that all potential side effects are disclosed as per regulatory requirements.

If you or a loved one have suffered from stomach paralysis or other serious side effects from Ozempic, Wegovy, or other GLP-1 drugs, you may be eligible to file a claim. 

Contact us for a free consultation, or use the chatbot on this page to find out if you qualify for an Ozempic Lawsuit.

March 21, 2024

The litigation surrounding Ozempic and other weight loss drugs is currently in the preliminary phase, and the number of lawsuits is expected to grow as the court sets the guidelines for filing cases.

A growing number of individuals are initiating legal actions against pharmaceutical leaders Eli Lilly and Novo Nordisk.

These firms manufacture a category of drugs known as GLP-1 agonists, which encompasses popular diabetes and weight loss medications like Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro.

The plaintiffs allege that they experienced severe digestive complications, including the necessity for gallbladder removal and the development of gastroparesis, due to using these drugs.

U.S. District Judge Gene E. K. Pratter in Philadelphia is overseeing the consolidation of these legal actions because of the similar complaints regarding the adverse effects of these medications.

A significant portion of these legal challenges is directed at Novo Nordisk, the producer of Ozempic and Wegovy, with the potential for the total number of cases to reach into the thousands as more affected individuals step forward.

Novo Nordisk asserts the safety and effectiveness of its GLP-1 drugs, pointing to their 13-year presence on the market and thorough safety assessments conducted in partnership with the U.S. Food and Drug Administration (FDA).

This legal battle underscores the enormous popularity of GLP-1 drugs in the United States, utilized for both diabetes treatment and weight management.

With projections indicating 30 million users by 2030 and revenues exceeding $1 billion, the implications are significant for both the pharmaceutical sector and those claiming injuries from these drugs.

If you or someone you know has suffered from gastroparesis or other health issues after using Ozempic or similar GLP-1 medications, you might qualify for a weight loss drug lawsuit.

Reach out to TruLaw for a free, no obligation consultation. 

For an immediate case evaluation, utilize the chatbot available on this webpage.

February 19, 2024

The Ozempic Lawsuit is developing, with legal actions focusing on claims related to severe gastrointestinal injuries attributed to the use of Ozempic and similar GLP-1 receptor agonist drugs.

As of early 2024, a federal panel has consolidated at least 55 lawsuits into a multidistrict litigation (MDL) in the Eastern District of Pennsylvania.

Ozempic Lawsuits allege that manufacturers Novo Nordisk and Eli Lilly, which also produces GLP-1 drugs, failed to adequately warn users about the potential for severe side effects such as gastroparesis (a condition causing delayed stomach emptying), intestinal obstruction, and other gastrointestinal injuries associated with these medications​​​​.

The consolidation into an MDL is aimed at streamlining the proceedings and ensuring consistent rulings across all cases.

The plaintiffs argue that despite the inclusion of warnings on the drug labels, the companies downplayed the severity of gastrointestinal issues.

The MDL includes claims related to a variety of drugs, including Novo Nordisk’s Ozempic, Wegovy, Rybelsus, and Eli Lilly’s Trulicity and Mounjaro.

Ozempic Lawyers anticipate that the number of lawsuits could grow significantly as part of the MDL​​.

A Louisiana federal judge largely rejected Novo Nordisk’s bid to dismiss the lawsuit, allowing the case to move forward, particularly on claims related to failure to warn about the risk of gastroparesis​​.

Ozempic Lawsuits and legal actions regarding other GLP-1 drugs highlight the importance of patients being fully informed about the potential side effects of weight loss medications, including those that could have severe implications for their health.

The consolidation of Ozempic Lawsuits into multidistrict litigation underscores the growing concern and legal scrutiny over the alleged severe side effects of Ozempic, Mounjaro, and other similar drugs.

If you or a loved one have suffered injuries after taking Ozempic or other similar drugs, you may be eligible to file an Ozempic Lawsuit. 

Contact us for more information or use the chatbot on this page to find out if you qualify for the Ozempic Lawsuit instantly.

February 18, 2024

Lawsuits against the makers of Ozempic and other similar drugs are growing, and the highly popularized medication is continuing to make news headlines for the wrong reasons.

A 60-year-old Illinois resident claims that her use of Ozempic resulted in a blocked bowel and violent vomiting, leading to a torn esophagus which required a week-long hospitalization.

Ozempic, a weekly injection that helps lower blood sugar by helping the pancreas make more insulin, is also used to help mitigate weight gain and can help with weight loss.

This case signals a significant moment in the growing controversy over the blockbuster weight loss drug’s alleged severe side effects.

The injured Illinoisan’s case joins nearly 60 others alleging that Ozempic and Wegovy, another Novo Nordisk product, caused stomach paralysis among other debilitating conditions and side effects.

With a centralization of lawsuits in a Pennsylvania federal court, pharmaceutical companies face a troubling legal challenge.

February 5, 2024

As of February 5, 2024, the legal proceedings concerning Ozempic continue, and attorneys are still open to taking on additional cases.

The latest update from the Judicial Panel on Multidistrict Litigation (JPML) indicates that there are currently seven Ozempic-related lawsuits grouped in the recently established Multidistrict Litigation (MDL).

In the U.S., MDLs are specialized judicial procedures used to efficiently manage multiple civil lawsuits that share common factors, such as similar legal questions, facts, or defendants.

This approach is particularly useful when various parties file lawsuits concerning shared issues, like the health concerns associated with Ozempic and other drugs.

These related lawsuits are combined into one federal district court for the pretrial phase.

The primary objective of an MDL is to streamline legal proceedings.

The Ozempic Lawsuit is still ongoing.